CBAN vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CBAN presents a conflicting profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the stock trades below its Graham Number ($25.44) and maintains a reasonable P/E of 12.43, the divergence between strong revenue growth (33.9%) and stagnant earnings growth (2.4%) is concerning. Technical trends are heavily bearish (10/100), offsetting the 'Strong Buy' analyst consensus. Overall, the valuation is attractive, but the underlying financial health metrics suggest high operational risk.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CBAN vs JPM: Head-to-Head Comparison
This page compares Colony Bankcorp, Inc. (CBAN) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.